Bolt Biotherapeutics Financials - Benzinga

Bolt Biotherapeutics Inc

BOLTNASDAQ

Trade with Public

Trade with Public

$3.59

0.030.84%

At close: Sep 21, 5:00 PM EST

$3.66

0.071.95%

After Hours: Sep 18, 5:07 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Bolt Biotherapeutics Financials

Bolt Biotherapeutics (BOLT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Bolt Biotherapeutics Q2 EPS $(4.57) Misses $(2.88) Estimate, Sales $5.000K Miss $500.000K Estimate

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.57) per share which missed the analyst consensus estimate of $(2.88) by 58.68 percent. This is a 2.47 percent decrease over losses of $(4.46) per share

Benzinga Newsdesk

PRO
Bolt Biotherapeutics Q1 EPS $(4.31) Misses $(2.85) Estimate, Sales $26.000K Miss $1.500M Estimate

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.31) per share which missed the analyst consensus estimate of $(2.85) by 51.23 percent. This is a 25.69 percent increase over losses of $(5.80) per share

Benzinga Newsdesk

PRO
Bolt Biotherapeutics Q4 EPS $(3.84) Beats $(4.30) Estimate, Sales $2.500M Beat $666.667K Estimate

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(3.84) per share which beat the analyst consensus estimate of $(4.30) by 10.7 percent. This is a 49.47 percent increase over losses of $(7.60) per share

Benzinga Newsdesk

PRO
Bolt Biotherapeutics Q3 EPS $(3.72) Beats $(5.53) Estimate, Sales $2.169M Beat $725.000K Estimate

Benzinga Newsdesk

PRO
Bolt Biotherapeutics Q2 EPS $(4.46) Beats $(6.27) Estimate, Sales $1.80M Beat $819.75K Estimate

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.46) per share which beat the analyst consensus estimate of $(6.27) by 28.83 percent. This is a 60.18 percent increase over losses of $(11.20) per share

Benzinga Newsdesk

PRO
Bolt Biotherapeutics Q1 EPS $(0.29) Beats $(0.36) Estimate, Sales $1.22M Beat $767.50K Estimate

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.36) by 19.44 percent. This is a 3.57 percent decrease over losses of $(0.28) per share

Benzinga Newsdesk